| Aug 21 |
Several Headwinds Dragged Cabaletta Bio (CABA) in Q2
|
| Aug 8 |
Cabaletta Bio GAAP EPS of -$0.56
|
| Aug 8 |
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Jul 8 |
Cabaletta Bio, Inc. (CABA): Why Are Analysts Loving This Shorted Stock Right Now?
|
| Jul 2 |
Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
|
| Jun 28 |
Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment
|
| Jun 14 |
Cabaletta Bio slips after early data for lead asset
|
| Jun 14 |
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
|
| May 29 |
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
|
| May 22 |
We Think Cabaletta Bio (NASDAQ:CABA) Can Afford To Drive Business Growth
|
